Cargando…
Evaluation of measles immunity in Turkey: is it still a threat?
BACKGROUND/AIM: Measles is one of the important vaccine-preventable diseases with many complications in childhood. This study presents cross-sectional seroepidemiological data, beginning from neonatal cord blood in infants to children under 6 years of age, about waning of measles antibody and tries...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350803/ https://www.ncbi.nlm.nih.gov/pubmed/30761852 http://dx.doi.org/10.3906/sag-1809-54 |
_version_ | 1783557341041393664 |
---|---|
author | KARAAYVAZ, Selda OĞUZ, Melahat Melek BEYAZOVA, Ufuk KORUKLUOĞLU, Gülay COŞGUN, Yasemin GÜZELKÜÇÜK, Zeliha BARAN AKSAKAL, Nur ŞAHİN DAĞLI, Figen |
author_facet | KARAAYVAZ, Selda OĞUZ, Melahat Melek BEYAZOVA, Ufuk KORUKLUOĞLU, Gülay COŞGUN, Yasemin GÜZELKÜÇÜK, Zeliha BARAN AKSAKAL, Nur ŞAHİN DAĞLI, Figen |
author_sort | KARAAYVAZ, Selda |
collection | PubMed |
description | BACKGROUND/AIM: Measles is one of the important vaccine-preventable diseases with many complications in childhood. This study presents cross-sectional seroepidemiological data, beginning from neonatal cord blood in infants to children under 6 years of age, about waning of measles antibody and tries to suggest the proper time for measles immunization. MATERIALS AND METHODS: A total of 564 blood samples consisting of neonatal cord blood and samples taken from infants and children at ages of 6, 9, 24–48, and 49–72 months were analyzed for measles seropositivity in a period of 6 months. RESULTS: Measles seropositivity rate was 72.5% in 109 cord blood samples, 2.6% in 117 infants of 6 months of age, and 3.6% in 111 infants of 9 months of age. Seropositivity was determined in 118 children at 24–48 months and in 109 children at 49–72 months and was 80.5% and 66%, respectively (P = 0.001). These children were vaccinated in the 12th month. CONCLUSION: Though measles immunization coverage is 97% in Turkey, population immunity is somewhat lower than expected. Increases of measles cases in Europe and the refugee problem in the country could easily lead to outbreaks. Implementing the first dose of the immunization at 9 months may be an option. |
format | Online Article Text |
id | pubmed-7350803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Scientific and Technological Research Council of Turkey |
record_format | MEDLINE/PubMed |
spelling | pubmed-73508032020-07-13 Evaluation of measles immunity in Turkey: is it still a threat? KARAAYVAZ, Selda OĞUZ, Melahat Melek BEYAZOVA, Ufuk KORUKLUOĞLU, Gülay COŞGUN, Yasemin GÜZELKÜÇÜK, Zeliha BARAN AKSAKAL, Nur ŞAHİN DAĞLI, Figen Turk J Med Sci Article BACKGROUND/AIM: Measles is one of the important vaccine-preventable diseases with many complications in childhood. This study presents cross-sectional seroepidemiological data, beginning from neonatal cord blood in infants to children under 6 years of age, about waning of measles antibody and tries to suggest the proper time for measles immunization. MATERIALS AND METHODS: A total of 564 blood samples consisting of neonatal cord blood and samples taken from infants and children at ages of 6, 9, 24–48, and 49–72 months were analyzed for measles seropositivity in a period of 6 months. RESULTS: Measles seropositivity rate was 72.5% in 109 cord blood samples, 2.6% in 117 infants of 6 months of age, and 3.6% in 111 infants of 9 months of age. Seropositivity was determined in 118 children at 24–48 months and in 109 children at 49–72 months and was 80.5% and 66%, respectively (P = 0.001). These children were vaccinated in the 12th month. CONCLUSION: Though measles immunization coverage is 97% in Turkey, population immunity is somewhat lower than expected. Increases of measles cases in Europe and the refugee problem in the country could easily lead to outbreaks. Implementing the first dose of the immunization at 9 months may be an option. The Scientific and Technological Research Council of Turkey 2019-02-11 /pmc/articles/PMC7350803/ /pubmed/30761852 http://dx.doi.org/10.3906/sag-1809-54 Text en Copyright © 2019 The Author(s) This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Article KARAAYVAZ, Selda OĞUZ, Melahat Melek BEYAZOVA, Ufuk KORUKLUOĞLU, Gülay COŞGUN, Yasemin GÜZELKÜÇÜK, Zeliha BARAN AKSAKAL, Nur ŞAHİN DAĞLI, Figen Evaluation of measles immunity in Turkey: is it still a threat? |
title | Evaluation of measles immunity in Turkey: is it still a threat? |
title_full | Evaluation of measles immunity in Turkey: is it still a threat? |
title_fullStr | Evaluation of measles immunity in Turkey: is it still a threat? |
title_full_unstemmed | Evaluation of measles immunity in Turkey: is it still a threat? |
title_short | Evaluation of measles immunity in Turkey: is it still a threat? |
title_sort | evaluation of measles immunity in turkey: is it still a threat? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350803/ https://www.ncbi.nlm.nih.gov/pubmed/30761852 http://dx.doi.org/10.3906/sag-1809-54 |
work_keys_str_mv | AT karaayvazselda evaluationofmeaslesimmunityinturkeyisitstillathreat AT oguzmelahatmelek evaluationofmeaslesimmunityinturkeyisitstillathreat AT beyazovaufuk evaluationofmeaslesimmunityinturkeyisitstillathreat AT korukluoglugulay evaluationofmeaslesimmunityinturkeyisitstillathreat AT cosgunyasemin evaluationofmeaslesimmunityinturkeyisitstillathreat AT guzelkucukzeliha evaluationofmeaslesimmunityinturkeyisitstillathreat AT baranaksakalnur evaluationofmeaslesimmunityinturkeyisitstillathreat AT sahindaglifigen evaluationofmeaslesimmunityinturkeyisitstillathreat |